Zemprocitinib, a next-generation JAK1 inhibitor, may tame rheumatoid arthritis that does not respond to at least one biologic disease-modifying antirheumatic drug, a phase 3 clinical trial finds.

These results support darovasertib plus Xalkori as a potential new standard of care if approved for HLA A*02:01-negative ...

Novel gedatolisib is currently under review at FDA for wild-type patients ...

Weekly subcutaneous injections of the novel B-cell inhibitor obexelimab significantly reduces disease flares and lowers toxic ...

NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors. A fusion ...

Agios Pharmaceuticals (NASDAQ:AGIO) has secured exclusive global rights to cevidoplenib, a next-generation oral SYK inhibitor ...

For patients diagnosed with advanced lung cancer driven by a specific genetic flaw called KRAS G12C, the first-line treatment ...

Deal gives Vyome entry into the fast-growing market for next-generation autoimmune and inflammatory disease drugs ...

Key milestone positions ART6043 as the most advanced Pol-theta inhibitor in clinical development; the potentially first-in-class program is ...

Lupeng Pharmaceutical today announced that the National Medical Products Administration (NMPA) has granted accelerated approval to rocbrutinib (development code: LP-168) for the treatment of adult ...

Switching off an enzyme that plays an important role in sugar metabolism, glycolysis, would normally be expected to cause serious problems for cells. Surprisingly, the opposite is also true: Cells can ...

Lupeng Pharma’s fourth-generation BTK inhibitor rocbrutinib approved in China for relapsed or refractory mantle cell lymphoma: Guangzhou, China Friday, June 5, 2026, 16:00 Hrs [ ...